Ars Pharmaceuticals Irl

Company snapshot

At ARS Pharma, we are committed to developing patient-friendly treatments to address serious issues related to needle-related risks, device portability and ease of use. Our innovative needle-free product empowers patients and caregivers to administer safe, effective therapies without hesitation or fear.

• 2 approved product(s) across US/EU regulatory metadata.
• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ars Pharmaceuticals Irl. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ars Pharmaceuticals Irl.

1. Jun 8, 2026 Clinical update

   EPI-U02 — Phase 2

2. Jun 8, 2026 Clinical update

   SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM — Phase 3

3. Jun 5, 2026 Clinical update

   Placebo — Phase 2

4. Jun 5, 2026 Clinical update

   IXCHIQ — Approved

5. Jun 5, 2026 Clinical update

   ARS-1 — Phase 2

View all clinical trial activity →

• What is Ars Pharmaceuticals Irl?

  Ars Pharmaceuticals Irl is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker SPRY. Primary therapeutic focus areas include Chronic Spontaneous Urticaria (CSU), Asthma, Urticaria, Upper Respiratory Tract Infection, Chikungunya Virus Infection. N

• Is Ars Pharmaceuticals Irl publicly traded?

  Yes. Ars Pharmaceuticals Irl is listed with ticker SPRY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Ars Pharmaceuticals Irl develop or market?

  We link 7 drug profile(s) where Ars Pharmaceuticals Irl is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ars-pharmaceuticals#company-drugs.

• What are the latest developments for Ars Pharmaceuticals Irl?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ars Pharmaceuticals Irl focus on?

  Ars Pharmaceuticals Irl focuses on Chronic Spontaneous Urticaria (CSU), Asthma, Urticaria based on our analysis of their pipeline programs and drug development activities.